Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway

Ethnopharmacological relevance: Pien-Tze-Huang (PZH)—a traditional Chinese medicine (TCM) compound—has been employed to treat various liver inflammation and tumors for over 10 decades. Interestingly, most of the pharmacological effects had been validated and explored toward liver ailment along with...

Full description

Bibliographic Details
Main Authors: Yuqin Zhang, Liping Hua, Chunfeng Lin, Mingzhou Yuan, Wei Xu, Anand Raj D., Baskar Venkidasamy, Carlos L. Cespedes-Acuna, Shivraj Hariram Nile, Guohong Yan, Haiyin Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.937484/full
_version_ 1797995241893003264
author Yuqin Zhang
Liping Hua
Chunfeng Lin
Mingzhou Yuan
Wei Xu
Anand Raj D.
Baskar Venkidasamy
Carlos L. Cespedes-Acuna
Shivraj Hariram Nile
Guohong Yan
Haiyin Zheng
author_facet Yuqin Zhang
Liping Hua
Chunfeng Lin
Mingzhou Yuan
Wei Xu
Anand Raj D.
Baskar Venkidasamy
Carlos L. Cespedes-Acuna
Shivraj Hariram Nile
Guohong Yan
Haiyin Zheng
author_sort Yuqin Zhang
collection DOAJ
description Ethnopharmacological relevance: Pien-Tze-Huang (PZH)—a traditional Chinese medicine (TCM) compound—has been employed to treat various liver inflammation and tumors for over 10 decades. Interestingly, most of the pharmacological effects had been validated and explored toward liver ailment along with pro-inflammatory conditions and cancer at the cellular and molecular level to date.Aim of the study: The present study aimed to investigate the therapeutic effect of PZH on autophagy and TGF-β1 signaling pathways in rats with liver fibrosis and hepatic stellate cell line (HSC).Materials and methods: Male SD rats with carbon tetrachloride (CCl4)-induced liver fibrosis were used as the animal model. Next, PZH treatment was given for 8 weeks. Afterward, the therapeutic effects of PZH were analyzed through a hepatic tissue structure by hematoxylin-eosin (H&E), Van Gieson (VG) staining, and transmission electron microscopy (TEM), activity of ALT and AST by enzyme-associated immunosorbent assay as well. Subsequently, mRNA and protein expression were examined by quantitative polymerase chain reaction (qPCR), Western blotting, and immunohistochemistry (IHC). Then, the cell vitality of PZH-treated HSC and the expression of key molecules prevailing to autophagy were studied in vitro. Meanwhile, SM16 (a novel small molecular inhibitor which inhibits TGFβ-induced Smad2 phosphorylation) was employed to confirm PZH’s effects on the proliferation and autophagy of HSC.Results: PZH pharmacologically exerted anti-hepatic fibrosis effects as demonstrated by protecting hepatocytes and improving hepatic function. The results revealed the reduced production of extracellular collagen by adjusting the balance of matrix metalloproteinase (MMP) 2, MMP9, and tissue inhibitor of matrix metalloproteinase 1 (TIMP1) in PZH-treated CCl4-induced liver fibrosis. Interestingly, PZH inhibited the activation of HSC by down-regulating TGF-β1 and phosphorylating Smad2. Furthermore, PZH down-regulated yeast Atg6 (Beclin-1) and microtubule-associated protein light chain 3 (LC3) toward suppressing HSC autophagy, and PZH exhibited similar effects to that of SM16.Conclusion: To conclude, PZH alleviated CCl4-induced liver fibrosis to reduce the production of extracellular collagen and inhibiting the activation of HSC. In addition, their pharmacological mechanisms related to autophagy and TGF-β1/Smad2 signaling pathways were revealed for the first time.
first_indexed 2024-04-11T09:57:12Z
format Article
id doaj.art-6110b7fd55954577afb77a5bdcbda23c
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-04-11T09:57:12Z
publishDate 2022-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-6110b7fd55954577afb77a5bdcbda23c2022-12-22T04:30:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.937484937484Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathwayYuqin Zhang0Liping Hua1Chunfeng Lin2Mingzhou Yuan3Wei Xu4Anand Raj D.5Baskar Venkidasamy6Carlos L. Cespedes-Acuna7Shivraj Hariram Nile8Guohong Yan9Haiyin Zheng10Pharmacy College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaPharmacy College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaCollege of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaCollege of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaPharmacy College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaDepartment of Biotechnology, Karpagam Academy of Higher Education (Deemed to be University), Coimbatore, Tamil Nadu, IndiaDepartment of Oral and Maxillofacial Surgery, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, IndiaPlant Biochemistry and Phytochemical Ecology Lab, Basic Sciences Department University of Bio Bio, Chillan, ChileSchool of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaAffiliated People’s Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaCollege of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, ChinaEthnopharmacological relevance: Pien-Tze-Huang (PZH)—a traditional Chinese medicine (TCM) compound—has been employed to treat various liver inflammation and tumors for over 10 decades. Interestingly, most of the pharmacological effects had been validated and explored toward liver ailment along with pro-inflammatory conditions and cancer at the cellular and molecular level to date.Aim of the study: The present study aimed to investigate the therapeutic effect of PZH on autophagy and TGF-β1 signaling pathways in rats with liver fibrosis and hepatic stellate cell line (HSC).Materials and methods: Male SD rats with carbon tetrachloride (CCl4)-induced liver fibrosis were used as the animal model. Next, PZH treatment was given for 8 weeks. Afterward, the therapeutic effects of PZH were analyzed through a hepatic tissue structure by hematoxylin-eosin (H&E), Van Gieson (VG) staining, and transmission electron microscopy (TEM), activity of ALT and AST by enzyme-associated immunosorbent assay as well. Subsequently, mRNA and protein expression were examined by quantitative polymerase chain reaction (qPCR), Western blotting, and immunohistochemistry (IHC). Then, the cell vitality of PZH-treated HSC and the expression of key molecules prevailing to autophagy were studied in vitro. Meanwhile, SM16 (a novel small molecular inhibitor which inhibits TGFβ-induced Smad2 phosphorylation) was employed to confirm PZH’s effects on the proliferation and autophagy of HSC.Results: PZH pharmacologically exerted anti-hepatic fibrosis effects as demonstrated by protecting hepatocytes and improving hepatic function. The results revealed the reduced production of extracellular collagen by adjusting the balance of matrix metalloproteinase (MMP) 2, MMP9, and tissue inhibitor of matrix metalloproteinase 1 (TIMP1) in PZH-treated CCl4-induced liver fibrosis. Interestingly, PZH inhibited the activation of HSC by down-regulating TGF-β1 and phosphorylating Smad2. Furthermore, PZH down-regulated yeast Atg6 (Beclin-1) and microtubule-associated protein light chain 3 (LC3) toward suppressing HSC autophagy, and PZH exhibited similar effects to that of SM16.Conclusion: To conclude, PZH alleviated CCl4-induced liver fibrosis to reduce the production of extracellular collagen and inhibiting the activation of HSC. In addition, their pharmacological mechanisms related to autophagy and TGF-β1/Smad2 signaling pathways were revealed for the first time.https://www.frontiersin.org/articles/10.3389/fphar.2022.937484/fullPien-Tze-Huangliver fibrosishepatic stellate cellautophagytransforming growth factor-β1matrix metalloproteinase
spellingShingle Yuqin Zhang
Liping Hua
Chunfeng Lin
Mingzhou Yuan
Wei Xu
Anand Raj D.
Baskar Venkidasamy
Carlos L. Cespedes-Acuna
Shivraj Hariram Nile
Guohong Yan
Haiyin Zheng
Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
Frontiers in Pharmacology
Pien-Tze-Huang
liver fibrosis
hepatic stellate cell
autophagy
transforming growth factor-β1
matrix metalloproteinase
title Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
title_full Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
title_fullStr Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
title_full_unstemmed Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
title_short Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway
title_sort pien tze huang alleviates ccl4 induced liver fibrosis through the inhibition of hsc autophagy and the tgf β1 smad2 pathway
topic Pien-Tze-Huang
liver fibrosis
hepatic stellate cell
autophagy
transforming growth factor-β1
matrix metalloproteinase
url https://www.frontiersin.org/articles/10.3389/fphar.2022.937484/full
work_keys_str_mv AT yuqinzhang pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT lipinghua pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT chunfenglin pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT mingzhouyuan pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT weixu pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT anandrajd pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT baskarvenkidasamy pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT carloslcespedesacuna pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT shivrajhariramnile pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT guohongyan pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway
AT haiyinzheng pientzehuangalleviatesccl4inducedliverfibrosisthroughtheinhibitionofhscautophagyandthetgfb1smad2pathway